Bruna Melchior1, Ives A Valenzuela2, C Gustavo De Moraes3, Jayter S Paula4, Massimo A Fazio5, Christopher A Girkin5, James Proudfoot6, George A Cioffi2, Robert N Weinreb6, Linda M Zangwill6, Jeffrey M Liebmann2. 1. From the Bernard and Shirlee Brown Glaucoma Research Laboratory (B.M., I.A.V., G.D.M., G.A.C., J.M.L.), Edward S. Harkness Eye Institute, Columbia University Irving Medical Center, New York, New York, USA; Department of Ophthalmology, Otorhinolaryngology and Head and Neck Surgery (B.M., J.S.P.), Ribeirao Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil. 2. From the Bernard and Shirlee Brown Glaucoma Research Laboratory (B.M., I.A.V., G.D.M., G.A.C., J.M.L.), Edward S. Harkness Eye Institute, Columbia University Irving Medical Center, New York, New York, USA. 3. From the Bernard and Shirlee Brown Glaucoma Research Laboratory (B.M., I.A.V., G.D.M., G.A.C., J.M.L.), Edward S. Harkness Eye Institute, Columbia University Irving Medical Center, New York, New York, USA. Electronic address: cvd2109@cumc.columbia.edu. 4. Department of Ophthalmology, Otorhinolaryngology and Head and Neck Surgery (B.M., J.S.P.), Ribeirao Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil. 5. Department of Ophthalmology (M.A.F., C.A.G.), University of Alabama-Birmingham, Birmingham, Alabama, USA. 6. Hamilton Glaucoma Center (J.P., R.N.W., L.M.Z.), Department of Ophthalmology, University of California-San Diego, La Jolla, California, USA.
Abstract
PURPOSE: To compare the rates of visual field (VF) progression between individuals of Black and White race and to investigate whether treatment effects may help explain differences previously reported between racial groups. DESIGN: Multicenter prospective observational cohort study. METHODS: Participants were patients in referral tertiary care glaucoma clinics with open angle glaucoma. Eyes were excluded who had <5 VF tests and <2 years of follow-up or any disease that could affect the optic nerve or the VF. The VF mean deviation (MD) slopes over time (dB/y) were calculated with linear regression models. Socioeconomic variables, rates of glaucoma surgery, medications, treated intraocular pressure (IOP), and central corneal thickness (CCT) were investigated. RESULTS: A total of 516 eyes were included with a mean (95% CI) follow-up time of 11.0 (range, 10.5-11.5) years and 15.0 (range, 14.1-15.8) visits. Participants of Black race were significantly younger (59.7 vs 66.9 years, P < .01) than those of White race. The mean CCT and socioeconomic variables were similar between Black and White groups (P = 0.20 and P = .56, respectively), as were treatment with topical medications (P = .90) and the rate of VF MD change (-0.24 [-0.31 to -0.17] dB/year vs -0.32 [-0.36 to -0.27], P = .11), despite higher treated mean IOP (14.9 [14.5 to 15.4] vs 14.0 [13.6 to 14.4] mm Hg, P = .03) and fewer trabeculectomies (29.5% vs 50.0%, P < .01) in the Black race group. CONCLUSIONS: Rates of VF progression were similar despite higher treated IOP in the Black race group. Mitigation of health access disparities in this study may have equalized previously reported different rates of VF progression between racial groups.
PURPOSE: To compare the rates of visual field (VF) progression between individuals of Black and White race and to investigate whether treatment effects may help explain differences previously reported between racial groups. DESIGN: Multicenter prospective observational cohort study. METHODS: Participants were patients in referral tertiary care glaucoma clinics with open angle glaucoma. Eyes were excluded who had <5 VF tests and <2 years of follow-up or any disease that could affect the optic nerve or the VF. The VF mean deviation (MD) slopes over time (dB/y) were calculated with linear regression models. Socioeconomic variables, rates of glaucoma surgery, medications, treated intraocular pressure (IOP), and central corneal thickness (CCT) were investigated. RESULTS: A total of 516 eyes were included with a mean (95% CI) follow-up time of 11.0 (range, 10.5-11.5) years and 15.0 (range, 14.1-15.8) visits. Participants of Black race were significantly younger (59.7 vs 66.9 years, P < .01) than those of White race. The mean CCT and socioeconomic variables were similar between Black and White groups (P = 0.20 and P = .56, respectively), as were treatment with topical medications (P = .90) and the rate of VF MD change (-0.24 [-0.31 to -0.17] dB/year vs -0.32 [-0.36 to -0.27], P = .11), despite higher treated mean IOP (14.9 [14.5 to 15.4] vs 14.0 [13.6 to 14.4] mm Hg, P = .03) and fewer trabeculectomies (29.5% vs 50.0%, P < .01) in the Black race group. CONCLUSIONS: Rates of VF progression were similar despite higher treated IOP in the Black race group. Mitigation of health access disparities in this study may have equalized previously reported different rates of VF progression between racial groups.
Authors: Cynthia Owsley; Gerald McGwin; Kay Scilley; Christopher A Girkin; Janice M Phillips; Karen Searcey Journal: Invest Ophthalmol Vis Sci Date: 2006-07 Impact factor: 4.799
Authors: Eve J Higginbotham; Mae O Gordon; Julia A Beiser; Michael V Drake; G Richard Bennett; M Roy Wilson; Michael A Kass Journal: Arch Ophthalmol Date: 2004-06